semaglutide south africa Wegovy After weight loss, Alzheimer's may

In clinical trials: Semaglutide: Approximately 7% discontinued due to adverse events Tirzepatide: Approximately 4-7% discontinued due to adverse events (dose dependent) Retatrutide: Approximately 6-10% discontinued due to adverse events (dose dependent) These rates are relatively close, suggesting that despite the differences in mechanism and side effect profiles, all three medications are tolerable for the vast majority of people who start them

This gives you an honest picture of what the medication switch specifically contributed

Tirzepatide delivered 20.2% body weight reduction versus 13.7% for semaglutide

At Edinburgh Weight Loss Clinic, the next step is a clinician-led assessment to confirm whether Wegovy tablets are suitable for you

The MHRA has reminded clinicians and patients about the small risk of severe acute pancreatitis with GLP-1 and dual GLP-1/GIP medicines

Mild stinging during injection is normal